$AKTS
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Matthew Roden
CEO
$19.50
Current Price
$942.77M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 6 | 9 | $114,311,628.00 | 6,350,646 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | Foley Todd Director | Purchase | 232,870 | $18.00 | $4,191,660.00 | View Details |
| Jan 12, 2026 | MPM BIOVENTURES 2018, L.P. 10% Owner | Purchase | 1,112,777 | $18.00 | $20,029,986.00 | View Details |
| Jan 12, 2026 | GADICKE ANSBERT 10% Owner | Purchase | 1,112,777 | $18.00 | $20,029,986.00 | View Details |
| Jan 12, 2026 | EcoR1 Capital, LLC Director | Purchase | 2,077,779 | $18.00 | $37,400,022.00 | View Details |
| Jan 12, 2026 | EcoR1 Capital, LLC Director | Purchase | 144,443 | $18.00 | $2,599,974.00 | View Details |
| Jan 12, 2026 | Vida Ventures II, LLC 10% Owner | Purchase | 22,545 | $18.00 | $405,810.00 | View Details |
| Jan 12, 2026 | Vida Ventures II, LLC 10% Owner | Purchase | 812,455 | $18.00 | $14,624,190.00 | View Details |
| Jan 12, 2026 | Kim Helen Susan Director | Purchase | 812,455 | $18.00 | $14,624,190.00 | View Details |
| Jan 12, 2026 | Kim Helen Susan Director | Purchase | 22,545 | $18.00 | $405,810.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: